1. No category

Buy Now
Hematological Disorder Drugs And Diagnostics Market: Global Industry
Analysis, Market Size and Forecast 2022_Brisk Insights
According to a recently published report, the global Hematological Disorder
Drugs And Diagnostics Market for hematological disorder is expected to grow at
the CAGR 5.6% during 2015-2022. The segmentation of global hematological
disorder drugs and diagnostics market is based on product, end-users and
geography. The report on global hematological disorder drugs and diagnostics
market forecast 2015-2022 (product, end-users and geography) provides detailed
overview and predictive analysis of the market.
Browse Here For Full Report with
ToC: http://www.briskinsights.com/report/hematological-disorder-drugs-anddiagnostics-market
The growth and demand of the global hematological disorder drugs and diagnostics
market is very high in developed and developing countries. In recent time, major
drivers that accelerate the global hematological disorder drug and diagnostics
market are increasing. The frequent occurrence of blood related disorders, growing
acceptance of automated hematology devices, and increasing expenditure in R&D
in the pharmaceutical sector are some of the major key drivers of the market.
According to the data collected by Lymphoma and Leukemia Society (LLS),
around 10% of US population was diagnosed with blood related disorders like
myeloma, leukemia and lymphoma. Moreover, as per the data stated by the
National Hemophilia Foundation, there are around 400,000 cases of hemophilia
globally. It has been estimated that the geriatric population aged over 65 will cross
over the 80 million mark by the year 2050, which will be a major driver for this
market in near future. Development of Point of Care (POC) diagnostics, cohesive
use of cytometry techniques and analyzers etc. are the major opportunities in
global hematological disorders drugs and diagnostic market. POC diagnostics
remains major field of interest among laboratories and a significant growth area for
this market. POC techniques can be used in the absence of specialized personnel,
in extreme field conditions or even at the bedside with no or limited infrastructure;
and also, without specialized maintenance services. Though POC techniques is not
Buy Now
a solution for all diagnostic needs, it is still a major opportunity in this market.
However, involvement of government and stringent regulations; lesser adoption in
developing economies; and, high cost of hematology diagnostics devices are major
restraints hampering the potential of global hematological disorders drugs and
diagnostics market.
Scope of the report
1. Global Hematological Disorder Drugs and Diagnostics Market by Product
2012- 2022 ($ billion)
1.1. Analyzers
1.2. Reagents
2. Global Hematological Disorder Drugs and Diagnostics Market by Endusers 2012- 2022 ($ billion)
2.1. Academic and research institutes
2.2. Hospitals
2.3. Clinical Laboratories
3. Global Hematological Disorder Drugs and Diagnostics Market Regional
Outlook 2012-2022 ($ billion)
3.1. North America
3.2. Europe
3.3. Asia Pacific
3.4. Middle East & Africa
3.5. Central & South America
4. Company profiles
4.1. Abbot Laboratories
4.2. Amgen
4.3. Beckman Coulter
4.4. Biogen Idec
4.5. Biorad Laboratories
4.6. Bristol-Myers Squibb
Buy Now
4.7. Eli Lilly And Company
4.8. Hemocue Ab
4.9. Horbia
4.10. Mindray Medical International
4.11. Nihon Kohden
4.12. Pfizer
4.13. Roche Diagnostics A/S
4.14. Siemens Ag
4.15. Sysmex
Blog : http://www.pdfdevices.com/global-hematological-disorder-drugs-anddiagnostics-market-is-expected-to-grow-at-the-cagr-of-5-6-during-2015-2022brisk-insights/
About Us :
Brisk Insights is a global market research firm. Our insightful analysis is focused
on developed and emerging markets. We identify trends and forecast markets with
a view to aid businesses identify market opportunities optimize strategies.
Contact Us:
Jennifer Smith
Office 1094
109 Vernon House
Friar Lane
nottingham
NG1 6DQ
United Kingdom
Phone : +448081890034 (UK)
Website : http://www.briskinsights.com/